AK112 for high-risk liver cancer after surgery
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer that can be removed with surgery.
- Your tumor has one or more features that put it at high risk for coming back (for example, larger than 5 cm, has spread into blood vessels, or your AFP level is very high).
- You have not had any prior treatment for liver cancer (like chemotherapy, targeted therapy, immunotherapy, or radiation).
- You are between 18 and 75 years old, in good enough health to undergo surgery, and your liver and kidney function are adequate.
- You do not have active infections (like uncontrolled hepatitis B or C, tuberculosis) or other cancers in the last 5 years (except some skin or early-stage cancers).
- You haven't had any serious bleeding issues or blood clots in the past 6 months, and you are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial tests if adding a new combination of drugs (AK104 and lenvatinib) to a standard liver cancer procedure called TACE is more effective than TACE alone. It is for people whose liver cancer has not spread and cannot be removed by surgery, but who are well enough to receive these treatments.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
This trial tests a new combination of two immunotherapy drugs, cadonilimab and AK112, as a second option for people with advanced liver cancer who have already tried standard first-line treatment and it stopped working or caused too many side effects.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.